Reduced lung function and the risk of out-of-hospital sudden cardiac death.

References 1 Lipworth B. Targeting the small airways asthma phenotype: if we can reach it, should we treat it? Ann Allergy Asthma Immunol 2013; 110: 233–239. 2 Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836–844. 3 Anderson WJ, Zajda E, Lipworth BJ. Are we overlooking persistent small airways dysfunction in communitymanaged asthma? Ann Allergy Asthma Immunol 2012; 109: 185–189. 4 Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338. 5 Shi Y, Aledia AS, Tatavoosian AV, et al. Relating small airways to asthma control by using impulse oscillometry in children. J Allergy Clin Immunol 2012; 129: 671–678. 6 Shi Y, Aledia AS, Galant SP, et al. Peripheral airway impairment measured by oscillometry predicts loss of asthma control in children. J Allergy Clin Immunol 2013; 131: 718–29. 7 Rao DR, Gaffin JM, Baxi SN, et al. The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity. J Asthma 2012; 49: 586–592. 8 Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215–1222. 9 Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999; 104: S258–S267. 10 Nicolini G, Chetta A, Simonazzi A, et al. Both bronchial and alveolar exhaled nitric oxide are reduced with extrafine beclomethasone dipropionate in asthma. Allergy Asthma Proc 2010; 31: 85–90. 11 Cohen J, Postma DS, Douma WR, et al. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J 2011; 37: 532–540. 12 Juniper EF, Price DB, Stampone PA, et al. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121: 1824–1832. 13 Price D, Martin RJ, Barnes N, et al. Prescribing practices and asthma control with hydrofluoroalkanebeclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010; 126: 511–518. 14 Barnes N, Price D, Colice G, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 2011; 41: 1521–1532. 15 Colice G, Martin RJ, Israel E, et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J Allergy Clin Immunol 2013; 132: 45–54.